Colorectal Cancer Coalition

Trial of New Drug to Blocks Cell Changes Available at NIH Clinical Center

An oral drug that blocks activity of enzymes that change proteins in cells that leads to cancer is being tested at the National Institutes of Health.

R935788 or Fostamatinib, a protein kinase inhibitor, is in a Phase II clinical trial for patients with several types of advanced cancer, including colorectal cancer.  Patients whose cancer has gotten worse on previous treatment are eligible to participate.  The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland.

Patients will take fostamatinib twice a day during 4 week cycles.  They’ll see a doctor at the NIH Clinical Center at the beginning of each cycle.  Weekly blood tests and blood pressure checks can be done in an outpatient clinic or by the patient’s own doctor.

There is no charge for medical care received at the National Institutes of Health (NIH) Clinical Center in Bethesda. Patients need to pay their own travel costs for the first screening visit, but once enrolled, the National Cancer Institute pays for transportation to the Washington area.  During outpatient visits, NCI pays a small daily amount for for hotel and meals.

Patients are encouraged to maintain their own insurance to cover health care costs outside of the NIH Clinical Center.

To be considered for the trial, patients or their doctors should contact research nurses:

• Janelle Bingham, R.N.
• Phone: 301-435-2715
• jbingham@mail.nih.gov

or

• Mary Ann Yancey, R.N.
• Phone: 301-435-9227
• yancym@mail.nih.gov

Shivaani Kummar, MD is leading the study.  She can be reached at 301-435-5402 or  kummars@mail.nih.gov

Find more answers to  your questions about the trial.  A full description is on the NCI Clinical Trials PDQ.

This news article was originally posted on July 30th, 2009 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on July 30th, 2009
Tags: clinical trials, fostamatinib, NIH Clinical Center

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Name Email (hidden) URL Comments (Basic HTML is allowed - a href, strong, em, blockquote)